What is the true risk of a pharmacokinetic drug–drug interaction?

By Fuhr Uwe  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 10, 2007-10 ,pp. : 897-899

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic drug–drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 6, 2015-11 ,pp. : 407-417

John Wiley & Sons Inc

Access to resources Recommend Favorite

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

By  

Clinical Pharmacology In Drug Development, Vol. 7, Iss. 2, 2018-02 ,pp. : 143-150

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol

By van den Bongard H.J.G. Desirée   Sparidans Rolf W.   Critchley David J.P.   Beijnen Jos H.   Schellens Jan H.M.  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 151-158

Springer Publishing Company

Access to resources Recommend Favorite

Drug-Drug Interaction Prediction Assessment

By Zhou Jihao  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 4, 2009-07 ,pp. : 641-657

Taylor & Francis Ltd

Access to resources Recommend Favorite